Sheel Biotech Reports Zero Pending Investor Complaints for Q2 FY27
Sheel Biotech Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 8:47 pm
Sheel Biotech Reports Zero Pending Investor Complaints for Q2 FY27 Sheel Biotech Limited submitted its quarterly investor grievance report under Regulation 13(3) of SEBI (LODR) Regulations, 2015, for the quarter ended 30th Sep'26. As certified by its Registrar and Share Transfer Agent, Skyline Financial Services Pvt Ltd, the company recorded zero investor complaints pending at the beginning of the quarter, received zero complaints, resolved zero, and closed the period with nil pending complaints across all platforms, including SEBI SCORES, SEBI ODR Portal, and stock exchanges.
Original exchange filing (PDF)
More announcements from Sheel Biotech Ltd
- Sheel Biotech Limited has informed the Exchange regarding 'Investor Presentation'. 路 17 Nov 2026
- Sheel Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Sheel Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 13 Nov 2026
- Monitoring Agency Report for the Half year ended on 30th September, 2026. 路 13 Nov 2026
- SHEEL BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 13 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 13 Nov 2026
- Sheel Biotech Limited has informed the Exchange about receipt of Award of Work having contract value of Rs. 1.72 Crore from Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu (SKUAST-Jammu) for blueberry production. 路 30 Oct 2026
- Sheel Biotech Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q2 FY 2026 路 13 Oct 2026
